Big Pharma's Next Billion-Dollar Bet Is Magic Mushrooms, MDMA And LSD. Could Psychedelic Drugs...
ตัวอย่างเสียงทั้งหมด
0:00
0:00
#1
Pharmaceutical giant Eli Lilly has agreed to acquire clinical-stage biotech firm AtaiBeckley for up to 3.8 billion dollars, marking a watershed moment in mental healthcare.
製藥巨頭禮來已同意以高達 38 億美元的價格收購臨床階段的生物技術公司 AtaiBeckley，這標誌著精神醫療領域的一個分水嶺時刻。
#2
Far from being merely another billion-dollar acquisition, the deal represents the most definitive endorsement yet of psychedelic drugs by mainstream medicine.
這筆交易絕非僅是另一樁數十億美元的收購案，而是代表了主流醫學界迄今對迷幻藥物最明確的支持。
#3
Substances once relegated to counterculture movements and widely dismissed by the medical establishment have now secured a prominent place in corporate strategy.
曾經被歸類於非主流文化運動並受到醫療主流普遍排斥的物質，如今已在企業策略中取得了顯著的地位。
#4
Central to this landmark transaction is BPL-003, a synthetic formulation of 5-MeO-DMT, a naturally occurring psychedelic compound administered as an intranasal spray.
這項里程碑式交易的核心是 BPL-003，這是一種 5-MeO-DMT 的合成配方，為一種天然存在的迷幻化合物，以鼻噴劑形式給藥。
#5
The therapy targets treatment-resistant depression, a particularly debilitating condition in which patients fail to respond to conventional antidepressants.
這種療法針對難治型憂鬱症，這是一種特別令人衰弱的疾病，患者對傳統的抗憂鬱藥物無法產生反應。
#6
An estimated four million Americans suffer from this condition, underscoring both the vast unmet medical need and the commercially attractive opportunity it presents.
估計有四百萬名美國人患有這種疾病，這凸顯了龐大且未被滿足的醫療需求，以及該疾病所帶來的具商業吸引力的機會。
#7
The optimism surrounding BPL-003 is far from unfounded.
圍繞著 BPL-003 的樂觀情緒絕非毫無根據。
#8
Positive Phase 2b clinical research results, reported last year, demonstrated rapid and sustained reductions in depressive symptoms among patients with treatment-resistant depression.
去年公布的 2b 期臨床研究正面結果顯示，在難治型憂鬱症患者中，憂鬱症狀得到了快速且持續的緩解。
#9
Subsequently, the United States Food and Drug Administration granted the therapy its Breakthrough Therapy Designation, a status reserved exclusively for treatments showing substantial improvement over existing options.
隨後，美國食品藥物管理局授予該療法「突破性療法認定」，這一地位專門保留給與現有選擇相比顯示出顯著改善的治療方法。
#10
This designation can significantly accelerate the regulatory review process, potentially bringing the drug to market sooner than conventional timelines would permit.
這項認定能顯著加速監管審查流程，有可能使該藥物比傳統時程所允許的時間更早上市。
#11
Nevertheless, industry analysts have cautioned that considerable hurdles remain before psychedelic drugs achieve widespread clinical adoption.
然而，行業分析師警告，在迷幻藥物獲得廣泛臨床採用之前，仍存在相當大的障礙。
#12
Regulatory frameworks for substances such as MDMA and LSD lag far behind the pace of clinical research, and questions persist regarding long-term safety, standardized dosing protocols, and the scalability of therapist-assisted treatment models.
針對 MDMA 和 LSD 等物質的監管框架遠遠落後於臨床研究的步伐，且關於長期安全性、標準化給藥方案以及治療師輔助治療模式之可推廣性的問題依然存在。
#13
Were these obstacles to prove insurmountable, even the most promising compounds could stall indefinitely in the approval pipeline.
要是這些障礙被證明是無法克服的，即使是最有前景的化合物也可能會在審批流程中無限期停滯不前。
#14
What remains beyond dispute is that this billion-dollar acquisition has irrevocably altered the trajectory of psychedelic medicine.
毋庸置疑的是，這筆數十億美元的收購案已不可逆轉地改變了迷幻藥物的發展軌跡。
#15
Should BPL-003 ultimately secure regulatory approval, it could herald a paradigm shift in how psychiatry addresses conditions that have long defied conventional treatment.
一旦 BPL-003 最終獲得監管部門的批准，它可能會預示著精神病學在應對長期抗拒傳統治療的病症方面，將發生典範轉移。
#16
Whether this bold pharmaceutical gamble pays off may well determine the future landscape of mental healthcare for decades to come.
這場大膽的製藥博弈是否能取得回報，很可能將決定未來數十年精神醫療領域的格局。